資料下載
Data download
熱門搜索：
Fitzgerald Industries International代理
Envirologix 轉(zhuǎn)基因快速檢測試紙
Epitomics現(xiàn)貨抗體目錄
ABgene代理30
EVE™ Slide（EVE細(xì)胞計數(shù)板）
Cayman Chemical 特約代理
法國ID-VET
美國Sutter 玻璃毛坯 BF100-50-10
Sinobio公司產(chǎn)品介紹
genview
polysciences公司中國總代理
D12079BWestern Diet(高純度飼料)
Abcam代理
TEAA Solution（貨號：553303;SP5890）
LSPN-50ABMI公司LYSOSTAPHIN中國總代理
天然小鼠補(bǔ)體C1q蛋白
發(fā)布時間：2024/3/4
點(diǎn)擊次數(shù)：454
matriksbiotek2024年價格表
Matriks Biotek專門生產(chǎn)針對抗體藥的ELISA試劑盒，用于檢測抗體藥的體內(nèi)含量或因用于產(chǎn)生的針對相應(yīng)抗體藥的抗體的體內(nèi)含量。Matriks Biotek®, SHIKARI®和KLONART®為Matriks生物技術(shù)公司注冊的產(chǎn)品商標(biāo)。其產(chǎn)品達(dá)到ISO 13485 & CE IVD標(biāo)準(zhǔn)。
MatriksBiote抗體藥是一類相對新型的生物制劑。檢測抗體藥及其抗體水平在治療和個性化用藥上具有重要意義。大量的臨床和制藥公司都在致力于抗體藥物的濃度水平和療效的研究。
特別告知：為保證產(chǎn)品質(zhì)量與良好性能，所以在購買相應(yīng)產(chǎn)品的同時我司會收取一定量的運(yùn)輸費(fèi)用！?。”敬螆髢r有效時間為2024年1月8日---2024年12月14日。
| 貨號 | 品名 | 規(guī)格 | 價格 | 品牌 | 貨期 | 價格來源 |
| ABA-FD-ORE | Abatacept (Orencia®) Free drug | 96T | 13541.38 | matriksbiotek | 3-4周 | 上海起發(fā) |
| ABA-QLS-ORE | Abatacept (Orencia®) Antibody screening - Qualitative | 96T | 13541.38 | matriksbiotek | 3-4周 | 上海起發(fā) |
| ABA-QNS-ORE | Abatacept (Orencia®) Antibody screening - Quantitative | 96T | 13541.38 | matriksbiotek | 3-4周 | 上海起發(fā) |
| ADA-FD-HUM | Adalimumab (Humira®) Free drug | 96T | 11834.48 | matriksbiotek | 3-4周 | 上海起發(fā) |
| ADA-QLS-HUM | Adalimumab (Humira®) Antibody screening - Qualitative | 96T | 11834.48 | matriksbiotek | 3-4周 | 上海起發(fā) |
| ADA-QNFT-HUM | Adalimumab (Humira®) Antibody screening - Free/Total semiquantitative | 96T | 12289.66 | matriksbiotek | 3-4周 | 上海起發(fā) |
| ADA-QNS-HUM | Adalimumab (Humira®) Antibody screening - Quantitative | 96T | 12289.66 | matriksbiotek | 3-4周 | 上海起發(fā) |
| ADA-SPEC-ADA | Adalimumab (Humira®) Free drug / Specific | 96T | 12289.66 | matriksbiotek | 3-4周 | 上海起發(fā) |
| AFL-FD-EYL | Aflibercept (Eylea®) Free drug | 96T | 12289.66 | matriksbiotek | 3-4周 | 上海起發(fā) |
| AFL-FD-SENS-EYL | Aflibercept (Eylea®) Free drug | 96T | 12289.66 | matriksbiotek | 3-4周 | 上海起發(fā) |
| AFL-QLS-EYL | Aflibercept (Eylea®) Antibody screening - Qualitative | 96T | 12289.66 | matriksbiotek | 3-4周 | 上海起發(fā) |
| AFL-QNS-EYL | Aflibercept (Eylea®) Antibody screening - Quantitative | 96T | 12289.66 | matriksbiotek | 3-4周 | 上海起發(fā) |
| ATE-FD-TEC | Atezolizumab (Tecentriq®) Free drug | 96T | 12289.66 | matriksbiotek | 3-4周 | 上海起發(fā) |
| ATE-QLS-TEC | Atezolizumab (Tecentriq®) Antibody screening - Qualitative | 96T | 12289.66 | matriksbiotek | 3-4周 | 上海起發(fā) |
| BEV-FD-AA | Bevacizumab (Avastin®) Free drug | 96T | 11834.48 | matriksbiotek | 3-4周 | 上海起發(fā) |
| CAN-FD-ILA | Canakinumab (Ilaris®) Free drug | 96T | 12289.66 | matriksbiotek | 3-4周 | 上海起發(fā) |
| CAN-QLS-ILA | Canakinumab (Ilaris®) Antibody screening - Qualitative | 96T | 12289.66 | matriksbiotek | 3-4周 | 上海起發(fā) |
| CAN-QNS-ILA | Canakinumab (Ilaris®) Antibody screening - Quantitative | 96T | 12289.66 | matriksbiotek | 3-4周 | 上海起發(fā) |
| DAR-FD-DAR | Daratumumab (Darzalex®) Free drug | 96T | 12289.66 | matriksbiotek | 3-4周 | 上海起發(fā) |
| DAR-QLS-DAR | Daratumumab (Darzalex®) Antibody screening - Qualitative | 96T | 12289.66 | matriksbiotek | 3-4周 | 上海起發(fā) |
| DEN-QNS-PRO | Denosumab (Prolia®) Antibody screening - Quantitative | 96T | 13541.38 | matriksbiotek | 3-4周 | 上海起發(fā) |
| DUR-FD-IMF | Durvalumab (Imfinzi®) Free drug | 96T | 12289.66 | matriksbiotek | 3-4周 | 上海起發(fā) |
| DUR-QLS-IMF | Durvalumab (Imfinzi®) Antibody screening - Qualitative | 96T | 12289.66 | matriksbiotek | 3-4周 | 上海起發(fā) |
| ETA-FD-ENB | Etanercept (Enbrel®) Free drug | 96T | 11834.48 | matriksbiotek | 3-4周 | 上海起發(fā) |
| EVO-FD-REP | Evolocumab (Repatha® ) Free drug | 96T | 13541.38 | matriksbiotek | 3-4周 | 上海起發(fā) |
| EVO-QLS-REP | Evolocumab (Repatha® ) Antibody screening - Qualitative | 96T | 13541.38 | matriksbiotek | 3-4周 | 上海起發(fā) |
| INF-FD-REMI | Infliximab (Remicade®) Free drug | 96T | 11834.48 | matriksbiotek | 3-4周 | 上海起發(fā) |
| INF-FD-REMS | Infliximab (Remsima®) Free drug | 96T | 11834.48 | matriksbiotek | 3-4周 | 上海起發(fā) |
| INF-QLS-REMI | Infliximab (Remicade®) Antibody screening - Qualitative | 96T | 11834.48 | matriksbiotek | 3-4周 | 上海起發(fā) |
| INF-QLS-REMS | Infliximab (Remsima®) Antibody screening - Qualitative | 96T | 11834.48 | matriksbiotek | 3-4周 | 上海起發(fā) |
| INF-QNFT-REMI | Infliximab (Remicade®) Antibody screening - Free/Total semiquantitative | 96T | 12289.66 | matriksbiotek | 3-4周 | 上海起發(fā) |
| INF-QNFT-REMS | Infliximab (Remsima®) Antibody screening - Total semiquantitative | 96T | 12289.66 | matriksbiotek | 3-4周 | 上海起發(fā) |
| INF-QNS-REMI | Infliximab (Remicade®) Antibody screening - Quantitative | 96T | 12289.66 | matriksbiotek | 3-4周 | 上海起發(fā) |
| INF-QNS-REMS | Infliximab (Remsima®) Antibody screening - Quantitative | 96T | 12289.66 | matriksbiotek | 3-4周 | 上海起發(fā) |
| INF-SPEC-INF | Infliximab (Remicade®) Free drug / Specific | 96T | 12289.66 | matriksbiotek | 3-4周 | 上海起發(fā) |
| NIV-FD-OPD | Nivolumab (Opdivo®) Free drug | 96T | 12289.66 | matriksbiotek | 3-4周 | 上海起發(fā) |
| PAL-FD-SYN | Palivizumab (Synagis® ) Free drug | 96T | 13541.38 | matriksbiotek | 3-4周 | 上海起發(fā) |
| PAL-QLS-SYN | Palivizumab (Synagis® ) Antibody screening - Qualitative | 96T | 13541.38 | matriksbiotek | 3-4周 | 上海起發(fā) |
| PAL-QNS-SYN | Palivizumab (Synagis® ) Antibody screening - Quantitative | 96T | 13541.38 | matriksbiotek | 3-4周 | 上海起發(fā) |
| PEM-FD-KEY | Pembrolizumab (Keytruda®) Free drug | 96T | 12289.66 | matriksbiotek | 3-4周 | 上海起發(fā) |
| RAN-FD-LUC | Ranibizumab (Lucentis®) Free drug | 96T | 12289.66 | matriksbiotek | 3-4周 | 上海起發(fā) |
| RIT-FD-RM | Rituximab (Rituxan®, Mabthera®) Free drug | 96T | 12289.66 | matriksbiotek | 3-4周 | 上海起發(fā) |
| RIT-QLS-RM | Rituximab (Rituxan®, Mabthera®) Antibody screening - Qualitative | 96T | 12289.66 | matriksbiotek | 3-4周 | 上海起發(fā) |
| RIT-QNS-RM | Rituximab (Rituxan®, Mabthera®) Antibody screening - Quantitative | 96T | 12289.66 | matriksbiotek | 3-4周 | 上海起發(fā) |
| SEC-FD-VER | Secukinumab (Cosentyx® , Verxant®) Free drug | 96T | 12289.66 | matriksbiotek | 3-4周 | 上海起發(fā) |
| SEC-QLS-VER | Secukinumab (Cosentyx® , Verxant®) Antibody screening - Qualitative | 96T | 12289.66 | matriksbiotek | 3-4周 | 上海起發(fā) |
| TOC-QNS-ACT | Tocilizumab (Actemra®) Antibody screening - Quantitative | 96T | 11834.48 | matriksbiotek | 3-4周 | 上海起發(fā) |
| TRA-FD-HH | Trastuzumab (Herceptin®, Herclon®) Free drug | 96T | 11834.48 | matriksbiotek | 3-4周 | 上海起發(fā) |
| UST-QLS-STE | Ustekinumab (Stelara®) Antibody screening - Qualitative | 96T | 12289.66 | matriksbiotek | 3-4周 | 上海起發(fā) |
| VED-FD-ENT | Vedolizumab (Entyvio®) Free drug | 96T | 12289.66 | matriksbiotek | 3-4周 | 上海起發(fā) |
| VED-QLS-ENT | Vedolizumab (Entyvio®) Antibody screening - Qualitative | 96T | 12289.66 | matriksbiotek | 3-4周 | 上海起發(fā) |
（*此為部分產(chǎn)品價格完整價格請下載文件）
關(guān)鍵詞：matriksbiotek、Matriks Biotek®、KLONART®、SHIKARI®、ELISA試劑盒
文件下載
當(dāng)前位置：
